In the BATTLE trial (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination), sorafenib achieved a better disease control rate in mutant-KRAS patients (61% versus 32%) compared with the combined other treatments (erlotinib, vandetanib or erlotinib) in chemorephractory NSCLC patients. This evidence concerns the gene KRAS and non-small cell lung carcinoma.